Cyber Monday saleUp to 70% OFF

PHARMA

ERIS Lifesciences for 25% gainsDate: 3 Dec’24 Symbol: ERIS Timeframe: Weekly ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels. The company, in the recently announced September quarter results has posted best ever revenues and operating profits. This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis. HINGLISH VERSION ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai. Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai. Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
NSE:ERISLong
by DhandhaPaani
IPCA LABS - Shorts below 1550 you may think of buying a put option or selling futures if IPCA labs closes below 1550 levels and then you can thank me later by boosting, liking and sharing the post. One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited. ' in October 1949. Thank you.
NSE:IPCALABShort
by piyushbafna000
Wochardt Ltd, classic Cup & handle break out (Long target ₹1500)Hello trader, Wockhardt Pharma is showing a promising technical setup with a classic cup and handle pattern breakout, supported by a significant volume spike . This pattern often signals the continuation of an uptrend, suggesting strong buying interest. Additionally, the RSI (Relative Strength Index) is above 60, indicating sustained strength and bullish momentum in the stock. These factors combined make wockhardt Pharma an attractive momentum play for traders, with the potential for continued gains if the breakout holds and volume persists. Note: This opinion is only for educational purpose, before trade please do your own analysis
NSE:WOCKPHARMALong
by Started_profitable
2
Granules India for 35%+ gainsDate: 3 Oct’24 Stock: Granules Timeframe: Daily chart Granules India seems to have begun its up move in Wave V of 5 which could end around 810-820 (>35% from current price of 595) as seen in the chart. High volumes and strong reversal of RSI supports this stance. This is not a trade recommendation. Please do your own analysis. Aisa lagata hai ki Granules India ne 5 ke Wave V mein apni badhat shuroo kar dee hai, jo 810-820 (595 kee vartamaan keemat se 35%) ke aasapaas samaapt ho sakatee hai, jaisa ki chart mein dekh sakte hain. Achhi volume aur RSI ka majaboot ulataav is rukh ka samarthan karta hai. Yeh koi vyaapaar ki rai nahin hai. Kripya apna vishleshan khud karein.
NSE:GRANULESLong
by DhandhaPaani
2
GRANULES INDIA LTDBuy above 595 All important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐨𝐟 𝐟𝐫𝐞𝐞 𝐨𝐟 𝐜𝐨𝐬𝐭.
NSE:GRANULESLong
by sreekumars
BIOCON LTD READY FOR A UPSWING (SWING TRADING SETUP)Since last weeks we have seen pharma sector is outperforming and this performance may continue. As per price action biocon ltd Has created a Cup but handle is still remaining. If this stock creates a handle which is highly possible then price can be bullish for few trading sessions. Price should sustain above Trend line then it will be good. For more confirmation wait for the price to come at resistance level and look for RSI above 70. If fails and test previous support then this Overview will be considered as NULL.(Conditions not fulfilled)
NSE:BIOCONLong
by jain_abhishek
PIRAMAL PHARMAPPL offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little's, Tetmosol, i-Pill and Polycrol.
BSE:PPLPHARMALong
by CannySunny
Gland Pharma breakout in one hour time frame Gland Pharma, founded in 1978 and headquartered in Hyderabad, India, is a pharmaceutical company specializing in injectable formulations. The company focuses on the development, manufacturing, and marketing of high-quality generic injectables, catering to a wide range of therapeutic areas. Gland Pharma is known for its robust product portfolio and strong presence in regulated markets, including the United States, Europe, Canada, and Australia. The company operates under stringent compliance with international regulatory standards, ensuring the delivery of safe and effective products. Sales Growth: Gland Pharma has demonstrated consistent sales growth over the past few years. For the fiscal year 2022-2023, the company's revenue was approximately ₹5,303 crore (around USD 660 million). This reflects a steady increase, driven by new product launches, geographical expansion, and increased penetration in existing markets. Strategic partnerships and collaborations have also played a crucial role in enhancing the company's sales performance. Earnings: Gland Pharma's earnings have shown significant improvement, supported by its robust sales growth and operational efficiencies. For the fiscal year 2022-2023, the company's net profit was approximately ₹1,397 crore (around USD 174 million). The company has maintained healthy profit margins through cost-effective manufacturing processes and economies of scale. Its focus on high-value products and complex generics has contributed to better pricing power and profitability. Debt: As of the latest financial reports, Gland Pharma has maintained a strong balance sheet with minimal debt. The company's debt levels are relatively low, allowing it to leverage its financial position for further growth and expansion without significant financial strain. THE COMPANY IS EXPECTED TO POST GOOD RESULTS THIS QUARTER ALSO.
NSE:GLANDLong
by ramkkyy
WANBURY LTD: 17-Year Resistance Shattered! Is This Pharma Stock WANBURY LTD: Breaking Resistance Like It's Going Out of Style! Technical Analysis: Breakout: Hold onto your hats, folks! Wanbury just smashed through a 17-year resistance level like a bull in a china shop... if the china shop had been reinforced for 17 years! Trend: The stock is in a strong uptrend, climbing faster than a squirrel on an espresso-coated tree. Volume: Huge volume activity observed. Traders are piling in like it's Black Friday at a discount pharmacy! Candle Pattern: That breakout candle is so bullish, it's practically wearing horns and pawing the ground. Support Levels: Previous resistance at 173.68 now likely to act as support. It's like the floor just became the ceiling, and Wanbury is redecorating the whole house! Fundamental Factors: Pharmaceutical sector seeing increased interest. Wanbury's producing more buzz than a beehive in a coffee shop. Potential new product launches or regulatory approvals could be fueling the rally. Risks: After such a strong move, a pullback is possible. Even rockets need to refuel sometimes! Keep an eye on broader market sentiment and sector-specific news. Trade Idea: Consider long positions with a stop loss below the breakout level. Target the psychological 200 level - it's time for Wanbury to join the 200 club! Remember, traders, timing is everything. You don't want to be fashionably late to this 17-year breakout party! Key Levels to Watch: Resistance turned support: 173.68 Next psychological resistance: 200.00 Stop loss consideration: Below 170.00 Disclaimer: This analysis is for educational purposes only. Always do your own research and manage your risk. Remember, the stock market is like a rollercoaster - thrilling, but it helps to have a strong stomach and know when to exit!
NSE:WANBURYLong
by TRADING-NASA